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Abstract: Although much emphasis has been placed on the primary presentations of breast 
cancer, little focus has been placed on how systemic illnesses may affect the breast. In this 
article, we discuss systemic illnesses that can manifest in the breast. We summarize the clini-
cal features, imaging, histopathology, and treatment recommendations for endocrine, vascular, 
systemic inflammatory, infectious, and hematologic diseases, as well as for the extramammary 
malignancies that can present in the breast. Despite the rarity of these manifestations of systemic 
disease, knowledge of these conditions is critical to the appropriate evaluation and treatment of 
patients presenting with breast symptoms.
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Introduction
Although breast cancer is the most worrisome problem involving the breast, systemic 
illnesses can affect the breast and cause concern related to diagnosis and treatment. 
In this article, we focus on the varying impact of different systemic illnesses on 
breast tissue.
Women exhibiting breast manifestations of systemic disease may present with a 
breast lump, skin changes, focal pain, and/or mammographic abnormalities. Evaluation 
of these symptoms depends on the overall presentation and may include diagnostic 
mammogram, breast ultrasound, biopsy of suspicious lesions, and, in some cases, mag-
netic resonance imaging of the breast. After exclusion of a primary breast malignancy 
or benign primary breast lesion, one must consider evaluation for systemic disease. 
This article provides an overview of breast manifestations of systemic disease and 
their evaluation.
Endocrine disease
Diabetic mastopathy
Diabetic mastopathy typically presents as a palpable breast mass that may be nontender, 
solitary or multiple, and unilateral or bilateral. It is most commonly identified in pre-
menopausal women with long-standing type 1 diabetes mellitus.1–3 Diabetic mastopathy 
accounts for less than 1% of benign breast disease but can be present in up to 13% of 
patients with type 1 diabetes.4 There have also been reports of diabetic mastopathy in 
older women in association with long-standing type 2 diabetes mellitus,5 but this finding 
was not reproduced in another retrospective cross-sectional study.3 Some cases have been 
identified in nondiabetic patients as well. Although the etiology of diabetic   mastopathy 
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is poorly defined, it remains   debatable as to whether it is 
actually a complication of diabetes mellitus. The lesions may 
spontaneously regress but the likelihood of recurrence is fairly 
high.1 There is no associated breast cancer risk.
On mammography, diabetic mastopathy is typically seen 
as a solid mass with asymmetric density, or it may appear 
as architectural distortion with features highly suggestive of 
malignancy. On sonograms, the lesions have a concerning 
appearance, most often irregular hypoechoic masses with 
worrisome features (Figure 1). If the patient has a known his-
tory of diabetes mellitus, it is possible to make the diagnosis 
of diabetic mastopathy on core needle biopsy, thus eliminat-
ing the need for an excisional biopsy. Magnetic resonance 
scanning of the breast has no role yet in establishing the 
diagnosis of diabetic mastopathy.
Diabetic mastopathy is a fibroinflammatory proliferation 
of breast tissue. Microscopic findings of lymphoid infiltrate 
of the periductal, perilobular, and perivascular structures 
are variably observed and may be patchy. In addition, dense 
keloid fibrosis is generally seen6 (Figure 2).
Excision of diabetic mastopathy is rarely necessary. 
There are no measures known to prevent its development 
or to lead to its resolution. Routine clinical examination is 
recommended and, in patients with a documented history 
of diabetic mastopathy, new occurrences can generally be 
managed conservatively unless suspicion of malignancy is 
raised on imaging.7
Vascular disease
Calciphylaxis
The rare, systemic medial calcification of arterioles, leading 
to ischemia and subcutaneous necrosis, has been labeled 
“calciphylaxis.”  This condition occurs most commonly in 
patients who have end-stage renal disease and are on hemodi-
alysis or who have undergone renal transplantation recently.8 
Only a few cases of calciphylaxis occurring in the breast have 
been reported in the medical literature,9 with six cases involv-
ing the breast after internal mammary artery   harvesting. Five 
of these six patients were on dialysis for end-stage renal 
disease.10–12 Breast findings included erythematous skin, peau 
d’orange, and large areas of ischemic necrosis.9
Mammographic findings include multiple and diffuse bilat-
eral calcifications with dystrophic or vascular morphology13 
and trabecular thickening indicative of parenchymal   edema.14 
Ultrasonographic changes include tissue edema and shad-
owing foci suggestive of extensive macrocalcification.14 
  Definitive diagnosis requires a biopsy.
Breast biopsy findings include fat necrosis, fibrosis, 
calcium deposits in the vessel walls, and calcifications of 
nonvascular tissue. The differential diagnosis includes breast 
cancer, especially inflammatory breast cancer. Most cases 
of calciphylaxis of the breast are treated with partial or total 
mastectomy. Complete healing of the breast lesion has been 
reported with total parathyroidectomy.13
Diffuse dermal angiomatosis
Diffuse dermal angiomatosis is a rare, acquired, cutaneous, 
reactive vascular disorder that was first described in 1994.15 
The benign vascular proliferation is characterized by poorly 
circumscribed, erythematous to violaceous painful lesions 
with frequent ulceration generally involving the extremi-
ties of patients who have severe vascular disease and other 
comorbid conditions. Diffuse dermal angiomatosis involving 
the breast is characterized by painful, violaceous, nonhealing, 
Figure 1 Diabetic mastopathy: ultrasound of a palpable abnormality shows an ill-defined mass-like area with decreased echogenicity and concerning features.
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ulcerating macules arising from an erythematous background 
on both breasts. The vascular-like lesions preferentially 
involve the underside of the breast.16–19 No specific findings 
on mammogram or ultrasound have been described in the 
medical literature. The diagnosis is made by punch biopsy 
of the skin lesion. The characteristic histologic features of 
diffuse dermal angiomatosis are the diffuse extravascular, 
interstitial proliferation of endothelial cells within the dermal 
stroma. An immunohistochemical stain for CD31 can be 
obtained for confirmation. Focal areas of proliferating cells 
may show an epithelioid morphology, vacuolated cytoplasm, 
and formation of small vascular channels.20 Treatment with 
isotretinoin, which has an antiangiogenic effect, has been 
reported to be beneficial in diffuse dermal angiomatosis 
involving the breast.16
Cardiovascular disease
The prevalence of breast arterial calcification in women pre-
senting for screening mammography has been reported to be 
about 14%.21 No clinical breast findings have been associated 
with breast arterial calcification detected by mammography. 
However, the presence of breast arterial calcification on 
mammograms indicates a substantially increased risk for 
development of cardiovascular disease or stroke. When an 
arterial wall is imaged longitudinally, breast arterial calcifica-
tion can be detected along the periphery of a tapered structure 
as two straight parallel calcium deposits (Figure 3). In con-
trast, when an arterial wall is imaged en face, breast arterial 
calcification can have a calcific ring configuration typical of 
arteries and distinct from breast ducts.21 Mammography is 
diagnostic for breast arterial calcification, and breast biopsies 
are not indicated for it. The pathologic findings of arterial 
calcifications in breast arterial vasculature are similar to those 
of cardiovascular disease. On mammograms, breast arterial 
calcification is an incidental finding and no specific treatment 
is indicated. However, since breast arterial calcification on a 
mammogram may be considered to be a marker for develop-
ment of cardiovascular disease, risk stratification and risk 
factor counseling are advisable.21
Systemic inflammatory disease
Giant cell arteritis
Although giant cell arteritis is a systemic disease, on 
rare occasions the breast may be the primary organ of 
  manifestation. In a review of the English medical literature 
up to 2008, Kadotani et al22 identified 20 reported cases, all 
of which were postmenopausal elderly women. Single or 
multiple lumps due to arteritis were present in 80% (16 of 
20 patients), and redness and tenderness in the absence of 
lumps were present in 10%. Breast involvement was bilat-
eral in 50% of the patients. Spontaneous breast pain and 
tenderness were presenting features in 85% of the patients.22 
Systemic symptoms such as low-grade fever, arthralgia, 
myalgia, and those suggestive of polymyalgia rheumatica 
were present in 65% of the patients.
There have been no reports of mass lesions or other dis-
tinctive findings by mammography or ultrasonography. In a 
recent case report23 of a patient presenting with a lump in her 
breast and a negative mammogram, ultrasound of a string-
like thickening in the right axillary tail of the breast revealed 
a “halo sign” (hypoechoic circumferential wall thickening 
indicating edema), which, compared with biopsy, has been 
reported to have a sensitivity of 69% and a specificity of 
82% for diagnosis of arteritis.24 In most cases reported in 
the medical literature, the diagnosis was made after exci-
sional biopsy (a considerable amount of tissue is required 
to make the diagnosis of giant cell arteritis). In rare cases, 
the diagnosis was established before biopsy on the basis of 
Figure 2 Breast biopsy showing lymphocytic mastitis consistent with diabetic mastopathy. Hematoxylin-eosin stains: Left, original magnification 400×; right top, original 
magnification 400×; right bottom, original magnification 400×.
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systemic symptoms22 and ultrasound   findings.23 Pathology 
shows fragmentation of the elastica in association with giant 
cell infiltration, intimal proliferation, and narrowing of the 
vascular lumina. Inflammatory cancer was suspected in four 
of seven cases reported by Kadotani et al.22
Prednisone is the treatment of choice. It has been shown 
to improve both general symptoms and breast-specific mani-
festations of giant cell arteritis.22
Polyarteritis nodosa
Polyarteritis nodosa of the breast is rare, with about a dozen 
cases reported in the medical literature.25 The clinical presenta-
tion ranges from localized disease involving the breast (skin 
and/or parenchyma) to breast manifestations as part of systemic 
polyarteritis nodosa. Polyarteritis nodosa can mimic breast can-
cer in patients presenting with a mass, and it can mimic breast 
infections such as mastitis or necrotizing fasciitis.
Imaging modalities have not been very helpful in estab-
lishing the diagnosis. Mammographic findings have not been 
reported in all cases, and those that have been reported have 
been negative except for findings in two25,26 patients who 
had calcification of arteries in both breasts as a prominent 
feature. The diagnosis of polyarteritis nodosa involving the 
breast is made by evaluating an adequate tissue sample from 
the breast.
Polyarteritis nodosa is characterized by segmental trans-
mural inflammation of muscular arteries. Polymorphonuclear 
leukocytes and mononuclear cells are found in the cellular 
infiltrate. Leukocytoclasis may also be noted. Arterial wall 
necrosis results in fibrinoid necrosis, which has a homoge-
neous, eosinophilic appearance. Disruptions of the internal 
and external elastic lamina may contribute to the development 
of aneurysmal dilatation. Lesions that appear to be of different 
ages are typically found within a single sample.27 Polyarteritis 
nodosa mimics breast cancer, inflammatory carcinomatosis, or 
breast infections, such as mastitis and necrotizing fasciitis.
Treatment of polyarteritis nodosa is guided by how the 
patient with disease presents. Débridement of localized 
necrotic skin and necrotic mammary tissue may be neces-
sary to manage the defect. If a tissue biopsy confirms the 
diagnosis of polyarteritis nodosa, then immunosuppressive 
treatment can commence.25
Wegener’s granulomatosis
Breast involvement is rare in patients with the uncommon dis-
ease of Wegener’s granulomatosis. Approximately 28 cases of 
breast involvement have been reported as occurring in women 
between the third and seventh decades of life.28 Breast involve-
ment may occur as the presenting symptom of Wegener’s 
granulomatosis or as a synchronous or   metachronous lesion in 
Figure 3 Bilateral mammogram showing benign arterial calcifications. (A) Right mediolateral oblique view shows arterial calcification (arrows) and (at top right of image) a 
pacemaker. (B) Left mediolateral oblique view shows arterial calcification (arrows).
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patients with systemic disease. Presenting symptoms include 
unilateral or bilateral breast masses, breast abscesses, necrotic 
lesions, and ulcerations.28,29
Mammographic findings have been reported as ill-defined or 
irregular masses suspicious for carcinoma.30   Ultrasonographic 
findings include irregular hypoechoic masses.30 The diagnosis 
is made by breast biopsy, but it can be difficult to establish if 
there are only small fragments of core needle biopsy material 
available versus an adequate tissue specimen.
Wegener’s granulomatosis is characterized by vasculitis 
of the medium-sized vessels that affects capillaries, venules, 
arterioles, and arteries. Necrotizing granulomatous inflam-
mation with central necrosis is the hallmark of the disease.28 
Associated with the granulomatous inflammation are 
multinucleated giant cells, plasma cells, lymphocytes, and 
neutrophils. Wegener’s granulomatosis may mimic breast 
cancer or granulomatous mastitis.
The initial treatment of most patients described in the med-
ical literature has been corticosteroids and   cyclophosphamide. 
In several cases, patients underwent excision of the breast 
lesion or a mastectomy. In almost all cases, symptoms 
improved substantially after immunosuppressive therapy.28
Sarcoidosis
Sarcoidosis is characterized as a systemic granulomatous 
disorder with no known etiology that can involve any organ 
system but frequently affects the lungs, hilar lymph nodes, 
eyes, skin, and joints. Breast involvement is rare, occurring 
in less than 1% of cases.31 Breast involvement can be either 
the sole manifestation, which is termed “primary mammary 
sarcoidosis,” or it can be part of a more obvious systemic 
disease. Patients may present either with a mass or without 
symptoms but with a mass detected on a mammogram.32
The mammographic abnormality is typically a mass, 
asymmetry, or an area of architectural distortion.33,34 
  Mammographic and ultrasonographic features are usually 
worrisome for malignancy. Biopsy, either surgical or image-
guided core needle, is required for diagnosis. Pathologic 
findings are noncaseating granulomas. Giant cells may or 
may not be seen. The differential diagnosis includes idio-
pathic granulomatous mastitis, tuberculosis, fungal infection, 
cat-scratch disease, and other autoimmune disorders with 
granulomatous inflammation.32
The usual first-line therapy is systemic corticosteroids. 
For patients with disease solely in the breast who do not 
respond to corticosteriods, there may be a role for surgical 
  excision although this has not been established as a   first-line 
therapy.31
Lupus mastitis
Lupus mastitis occurs in approximately 2% of patients with 
systemic lupus erythematosus.35 Up to 70% of patients have 
associated discoid skin lesions. Lupus mastitis is rarely 
the presenting symptom. Fewer than 25 cases have been 
described in the medical literature, with four cases reported 
in men. Breast findings on clinical examination include single 
or multiple subcutaneous nodules, which may be tender or 
painful and can progress to ulcerated lesions.35
The lesions are ill-defined on mammograms and sono-
grams and may or may not be associated with calcifications. 
Alternatively, calcifications may be present alone, which 
is suggestive of fat necrosis.35 Image-guided or excisional 
biopsy is needed to differentiate this lesion from breast 
cancer.
Pathologically, immune complex depositions are noted 
at the basement membrane of the dermal-epidermal junction 
and in the blood vessels in the area of the panniculitis.35 Key 
histopathologic findings are lobular lymphocytic panniculitis 
and hyaline fat necrosis.36 Lymphocytic vasculitis is also a 
common feature.
If insufficient biopsy tissue is present, the lesion may 
be mistaken for primary medullary carcinoma of the breast, 
especially if the tissue contains predominantly lymphoplas-
macytic inflammatory component. Diabetic mastopathy may 
also be in the differential diagnosis.35
Initial treatment typically consists of antimalarial agents 
or corticosteroids. Surgery can be considered in cases that 
do not respond to medical treatment.36
Infectious disease
Breast involvement in systemic infections is a rare condi-
tion but has been reported with tuberculosis, echinococcosis 
and other parasitic diseases, and actinomycosis. Breast 
tuberculosis may become a relevant problem with the 
increasing occurrence of tuberculosis related to acquired 
immune deficiency syndrome and tuberculosis as a global 
health concern.
Tuberculosis of the breast is a rare condition generally 
secondary to systemic infection, with breast tissue infection 
resulting from hematogenous lymphatic spread or from 
spread from a contiguous infection such as one in the chest 
wall.37,38 Clinical presentation is generally a breast lump that 
is firm to hard in consistency and can be mistaken for malig-
nancy, but it can also present as an ulcer or a discharging 
sinus on the skin overlying the breast, as a nipple discharge, 
or as peau d’orange if it is associated with extensive axil-
lary disease.
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Mammography is often inconclusive because the lesion 
may be seen as a round mass with ill-defined margins. On 
ultrasound, lesions are often hypoechoic or present as complex 
cysts. Ultrasound-guided cyst aspiration with cytology of the 
fluid may show epitheloid cell granulomas and necrosis but is 
often inconclusive. Histopathologic findings of biopsy speci-
mens of the mass demonstrate necrotizing granulomas.
Treatment of tuberculosis infection of the breast is with 
multidrug antitubercular therapy. Surgical intervention is 
needed only for drainage of a breast abscess or for inci-
sional or excisional biopsy of the mass. In some instances, 
a residual breast mass after antitubercular therapy may 
require surgical excision.37
Hematologic disease
Malignant lymphoma
Lymphoma of the breast can present as primary lymphoma, 
implying that there is no extramammary organ involve-
ment, and as secondary lymphoma with known extramam-
mary disease. Both conditions are rare, with primary breast 
lymphoma comprising about 0.1%–0.5% of all breast 
neoplasms and secondary breast lymphoma being slightly 
more common.39 Primary lymphoma can present as diffuse 
infiltration or as discrete and sometimes multiple nodules. 
Wong et al39 reviewed the Mayo Clinic experience with 
  primary non-Hodgkin’s lymphoma of the breast over 25 years 
(1973–1998) and identified 26 patients, 25 of whom were 
women with a median age of 60 (range 12–80) years at 
diagnosis. Twenty-four of the 26 patients presented with a 
breast lump. The median tumor size was 3.3 (range 1–10) cm. 
In contrast with tumors in primary breast lymphoma, breast 
masses in secondary breast lymphoma have been reported 
to be smaller, perhaps because of the shorter duration of the 
disease within the breast.40
Sabate et al40 noted significant differences between breast 
lymphoma and carcinoma on mammograms. The mean size 
of the tumor was larger in patients in the lymphoma group 
(4.6 cm versus 2–3 cm in patients in the carcinoma group). 
Architectural distortion was not noted in the lymphoma 
masses but was evident in the carcinoma group. Calcifica-
tions were not observed in any patients in the lymphoma 
group but were evident in 50% of those in the carcinoma 
group. Although a core biopsy may be adequate for diagnosis 
of a breast lymphoma, an excisional biopsy may be necessary 
to obtain adequate tissue for lymphoma subtyping.
Most primary breast lymphomas are non-Hodgkin’s 
  lymphoma. Although all histologic types of lymphoma have 
been described, primary breast lymphomas are most com-
monly B-cell lymphomas; about one-half are diffuse large 
B-cell lymphomas. Less common are breast lymphomas with 
an indolent histology (ie, follicular non-Hodgkin’s lymphoma 
or extranodal marginal zone lymphoma).
Treatment consists of local excision of the breast lym-
phoma, radiotherapy, and chemotherapy. The choice of che-
motherapy is based on the histologic subtype.   Mastectomy 
does not appear to improve survival.41
Plasmacytoma
Plasmacytoma may present as a palpable breast mass or, more 
unusually, as an incidental finding on mammography. It may 
occur as the initial presentation or in the setting of known 
multiple myeloma.42,43 In contrast with solitary plasmacytoma 
of the bone, extramedullary plasmacytoma is associated with 
symptomatic multiple myeloma in only 15% of patients.44
Mammographic findings include rounded, oval, and lobu-
lated masses, which can be solitary or multiple or both (Fig-
ure 4A and B). Occasionally, they present as diffuse infiltration 
of the breast. Ultrasound typically shows a hypoechoic mass 
that can be either well defined or ill defined (Figure 4C).42 Core 
biopsy is needed to differentiate plasmacytoma from primary 
breast cancer. Immunohistochemical staining reveals clonal 
plasma cells (Figure 5A) positive for κ or λ light chains44 
(Figure 5B).
Treatment consists of radiotherapy to the extramedullary 
plasmacytoma,44 unless there is significant systemic multiple 
myeloma, in which case treatment is for the systemic disease.
Amyloid
Amyloid of the breast is either localized or more commonly 
associated with systemic amyloidosis. As part of the systemic 
form, breast amyloid usually occurs as a late presentation 
of known amyloidosis in other visceral organs. In a case 
series from Boston Medical Center, Charlot et al45 found that 
localized amyloidosis of the breast represented only 0.5% 
of all the patients referred to the amyloid treatment center. 
Patients may present with either a breast mass40,46,47 or no 
breast findings on clinical examination.48
Mammographic findings include incidental masses, 
clustered microcalcifications, and focal asymmetry.49 Core 
needle biopsy or excisional biopsy aids diagnosis. Macroscopic 
 examination of biopsy specimens shows well-circumscribed 
solid gray tumors, whereas microscopic examination shows 
abundant hyaline pink material. Focal microcalcifications 
may be apparent, and amyloid stains are positive.50
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Figure 4 Plasmacytoma of the breast. Left mammogram shows (A) a small well defined mass (circle) in the left craniocaudal view and (B) an abnormal lymph node (arrows) 
in the mediolateral oblique view. (C) Ultrasound shows a hypoechoic mass (arrows) with hyperechoic rim.
Treatment for primary breast amyloidosis is surgical exci-
sion of the affected area. Treatment for secondary amyloidosis 
is done by treatment of the underlying systemic disease.45
Metastases from other solid  
organ primaries
Breast cancer is the most common type of primary malignancy 
in women, but metastatic spread to the breast from other solid 
organs, although rare, has been reported51–53 and may be the 
first sign of malignancy.54 On the basis of histologic diagnosis 
in clinical studies, the frequency of metastatic tumors in the 
breast from extramammary malignancies has been estimated 
to range from 0.2% to 1.3%.55 In a review from the Royal 
London Hospital of secondary neoplasms from other solid 
organs that metastasized to the breast, Georgiannos et al56 
reported that, over 90 years, metastases to the breast were 
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found to emanate from primary lung cancer, melanoma, 
or gastric, renal, endometrial, pancreatic, esophageal, and 
thyroid cancers (in descending order of frequency).
Williams et al57 found in a series of patients that a single 
mass was identified on mammography in 39.5% of patients 
and that multiple masses were identified in 33.7% of patients. 
However, of those patients who underwent breast imaging, 
16.3% had mammograms with no abnormal findings. The 
recommended diagnostic approach to metastases from other 
solid organ primaries is core biopsy for tissue diagnosis.
Immunohistochemistry is considered beneficial in dis-
tinguishing between primary breast cancers and metastases 
from other organs.57 In addition to findings of standard and 
specialized stains, estrogen-, progesterone-, and HER-2 
receptor–negative findings can help to differentiate metastatic 
tumors from primary breast cancers.
Treatment is focused on management of the primary 
cancer rather than on the metastatic lesion to the breast. 
However, Williams et al57 noted that if the metastatic disease 
burden is low, lumpectomy might be considered.
Conclusion
In summary, this review reports on breast lesions associated 
with systemic disorders and details the clinical presenta-
tion, imaging findings, pathologic findings, and treatment. 
Although such presentations are rare, an awareness of these 
associations and knowledge about the diagnosis and treatment 
of patients with such breast lesions is critical to determining 
appropriate evaluation and treatment. However, breast cancer 
always needs to be strongly considered in the differential 
diagnosis of breast abnormalities in such patients.
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